Analysis of FluidForm Bio Launches $1.24M Crowdfunding Round to Advance Bioprinted Diabetes Therapy - aVenture Research
The Business of Biofabrication
FluidForm Bio Launches $1.24M Crowdfunding Round to Advance Bioprinted Diabetes Therapy
FluidForm Bio, a regenerative medicine company developing 3D bioprinted cell therapies for diabetes, has launched a new fundraising campaign on StartEngine, aiming to raise up to $1.24 million through a convertible note offering. The Waltham-based company is pursuing a novel approach to treating type 1 diabetes using its proprietary FRESH™ (Freeform Reversible Embedding of Suspended…
An analysis reads this article and its sources, then explains what happened, who is involved, and what it means, quoting a source for each claim. Once written, every reader sees it here.
Analysis requires a paid plan or prepaid credits and uses your company research allowance.